Personalized therapy of type 2 diabetes mellitus
- Authors: Kiseleva T.A.1, Valeeva F.V.1, Islamova D.R.1
-
Affiliations:
- Kazan State Medical University
- Issue: Vol 40, No 5 (2023)
- Pages: 73-79
- Section: Review of literature
- URL: https://journals.rcsi.science/PMJ/article/view/254808
- DOI: https://doi.org/10.17816/pmj40573-79
- ID: 254808
Cite item
Full Text
Abstract
Currently, the contribution of genetic factors to the development of type 2 diabetes is becoming more obvious. Despite the available nine classes of hypoglycemic drugs, only 35–40 % of patients achieve an adequate glycemic control. One the reasons may be the genetic heterogeneity of diabetes mellitus. An increasing number of studies indicates that an individual set of gene polymorphisms can determine the therapeutic response to a particular drug and cause the development of undesirable effects. The article presents an overview of a new direction in the diagnosis and treatment of diabetes mellitus – personalized medicine. The pathogenetic mechanisms of the development of the disease, its heterogeneity and the difficulties of choosing the most effective hypoglycemic therapy are described. Data on the pharmacogenetic features of metformin are presented.
Full Text
##article.viewOnOriginalSite##About the authors
T. A. Kiseleva
Kazan State Medical University
Author for correspondence.
Email: tattiana@mail.ru
ORCID iD: 0000-0001-8959-093X
Candidate of Medical Sciences, Associate Professor, Department of Endocrinology
Russian Federation, KazanF. V. Valeeva
Kazan State Medical University
Email: tattiana@mail.ru
ORCID iD: 0000-0001-6000-8002
MD, PhD, Professor, Head of the Department of Endocrinology
Russian Federation, KazanD. R. Islamova
Kazan State Medical University
Email: tattiana@mail.ru
ORCID iD: 0000-0003-3639-6361
Clinical Resident, Department of Endocrinology
Russian Federation, KazanReferences
- Mannino G.C., Andreozzi F., Sesti G. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes Metab Res Rev. 2019; 35 (3): 3109. doi: 10.1002/dmrr.3109
- Imamovic Kadric S., Kulo Cesic A., Dujic T. Pharmacogenetics of new classes of anti-diabetic drugs. Bosn J Basic Med Sci. 2021; 21 (6): 659–671. doi: 10.17305/bjbms.2021.5646
- Global report on diabetes. Geneva: World Health Organization, 2018. License: CC BY-NC-SA (in Russian).
- Dedov I.I., Shestakova M.V. Personalized therapy for diabetes mellitus: the path from disease to the patient. Terapevticheskii arkhiv 2014; 86 (10): 4–9 (in Russian).
- Smushkin G., Vella A. Genetics of type 2 diabetes. Current Opinion in Clinical Nutrition and Metabolic Care 2010; 13 (4): 471–477. DOI: http://dx.doi.org/10.1097/MCO.0b013e32833a558d
- Voight B.F., Scott L.J., Steinthorsdottir V., et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42 (7): 579–589. doi: 10.1038/ng.609
- Vujkovic M., Keaton J.M., Lynch J.A., et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020; 52 (7): 680–691. doi: 10.1038/s41588-020-0637-y
- McCarthy M.I. Painting a new picture of personalised medicine for diabetes. Diabetologia 2017; 60 (5): 793–799. doi: 10.1007/s00125-017-4210-x
- Pearson E.R. Type 2 diabetes: a multifaceted disease. Diabetologia 2019; 62 (7): 1107–1112. doi: 10.1007/s00125-019-4909-y
- Kononenko I.V., Mayorov A.Yu., Koksharova E.O., Shestakova M.V. Pharmacogenetics of hypoglycemic agents. Diabetes mellitus. 2015; 18 (4): 28–34. doi: 10.14341/DM7681 (in Russian).
- Becker M.L., Pearson E.R., Tkáč I. Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol. 2013: 686315. doi: 10.1155/2013/686315
- Dawed A.Y., Zhou K., Pearson E.R. Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. Pharmgenomics Pers Med. 2016; 9: 17–29. doi: 10.2147/PGPM.S84854
- Wild H. The economic rationale for adherence in the treatment of type 2 diabetes mellitus. Am J Manag Care. 2012; 18 (3): S43–S48.
- Singh S., Usman K., Banerjee M. Pharmacogenetic studies update in type 2 diabetes mellitus. World J Diabetes. 2016; 7 (15): 302–315. doi: 10.4239/wjd.v7.i15.302
- Yan, Q. Pharmacogenomics in drug discovery and development. Humana Press 2010; 504.
- Deenen M.J., Cats A., Beijnen J.H., Schellens J.H. Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist 2011; 16 (6): 811–819. doi: 10.1634/theoncologist.2010-0258
- Pernicova I., Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014; 10 (3): 143–156. doi: 10.1038/nrendo.2013.256
- Miller R.A., Chu Q., Xie J., Foretz M., Viol-let B., Birnbaum M.J. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013; 494 (7436): 256–260. doi: 10.1038/nature11808
- Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012; 122 (6): 253–270. doi: 10.1042/CS20110386
- Gong L., Goswami S., Giacomini K.M., Altman R.B., Klein T.E. Metformin path-ways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012; 22 (11): 820–827. doi: 10.1097/FPC.0b013e3283559b22
- Madiraju A.K., Erion D.M., Rahimi Y. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014; 510 (7506): 542–546. doi: 10.1038/nature13270
- GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K., et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011; 43 (2): 117–120. doi: 10.1038/ng.735
- DeGorter M.K., Xia C.Q., Yang J.J., Kim R.B. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012; 52: 249–273. doi: 10.1146/annurev-pharmtox-010611-134529
- Umamaheswaran G., Praveen R.G., Damodaran S.E., Das A.K., Adithan C. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med. 2015; 15 (4): 511–517. doi: 10.1007/s10238-014-0322-564
- Dujic T., Zhou K., Donnelly L.A., Tavendale R., Palmer C.N., Pearson E.R. Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015; 64 (5): 1786–1793. doi: 10.2337/db14-1388